Drug Profile
Research programme: antibodies - AnaptysBio/Celgene Corporation
Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator AnaptysBio
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 23 Sep 2021 Preclinical development is ongoing in Inflammation (Parenteral) in USA (AnaptysBio pipeline, September 2021)
- 28 Jul 2021 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)